<p>&lt;&lt;Component 1 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Residual Sleepiness in Obstructive Sleep Apnea: The Role of Inflammation</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Program Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Timecode (00:00:22). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Panelists</strong></p>

<p>&lt;&lt;insert slide 3; Timecode (00:00:40). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Disclosure</strong></p>

<p>&lt;&lt;insert intra-activity question 1 (00:00:56)&gt;&gt;</p>

<p>&lt;&lt;insert slide 4; Timecode (00:00:57). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Segment Introduction </strong></p>

<p>&lt;&lt;insert slide 5; Chapter Title: Excessive Daytime Sleepiness; Timecode (00:01:25). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Excessive Daytime Sleepiness in OSA<sup>[1,2]</sup></strong></p>

<p>&#8226;	Trying to understand why these patients remain sleepy or why there is such a strong association with excessive sleepiness is a major problem </p>

<p>&lt;&lt;insert slide 6; Chapter Title: Arousal Threshold and Inflammation; Timecode (00:02:42).  &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Association of the Arousal Threshold with Inflammation and Sleepiness<sup>[3]</sup></strong></p>

<p>&#8226;	Waking up too easily to minor airway narrowing (low respiratory arousal threshold [ArTH]) is a key contributor to obstructive sleep apnea (OSA) pathophysiology</p>

<p>&#8226;	The extent to which a low ArTH phenotype contributes to daytime sleepiness and inflammation-related clinical sequelae in OSA is unclear</p>

<p>&#8226;	The aim of this study was to determine whether the ArTH correlated either with inflammatory markers or daytime sleepiness </p>

<p>&lt;&lt;insert slide 7; Timecode (00:03:26). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Arousal Threshold and Inflammation Study: Results<sup>[3]</sup></strong></p>

<p>&#8226;	When the study was adjusted:</p>

<p><tt>o	</tt> The relationship between the ArTH and that of the inflammatory marker C-reactive protein (CRP) disappeared</p>

<p><tt>o	</tt>There was no relationship between the ArTH and the sleepiness level</p>

<p>&lt;&lt;insert slide 8; Arousal Threshold and Depression; Timecode (00:06:05). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Depression and Arousal Threshold<sup>[4]</sup></strong></p>

<p>&#8226;	In patients with depression, sleep can be disrupted and fragmented</p>

<p>&#8226;	Sleep disruption could be contributing to the ArTH</p>

<p>&lt;&lt;insert slide 9; Chapter Title: Conclusion; Timecode (00:07:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Concluding Remarks </strong></p>

<p>&lt;&lt;Component 2 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Residual Sleepiness in Obstructive Sleep Apnea: Objective and Subjective Markers </strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: EDS in Adequately Treated OSA; Timecode (00:00:22). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;</strong> <strong>Excessive Daytime Sleepiness in Patients Adequately Treated With PAP<sup>[5]</sup></strong></p>

<p>&#8226;	This study looked at the correlation between subjective ratings and an objective test</p>

<p><tt>o	</tt>Subjective -- Epworth Sleepiness Scale (ESS)</p>

<p><tt>o	</tt>Objective -- Multiple Sleep Latency Test (MSLT)</p>

<p>&lt;&lt;insert slide 3;Chapter Title: Methods; Timecode (00:01:11). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Study Design<sup>[5]</sup></strong></p>

<p>&#8226;	Actigraphy approximates how stable a patient's sleep-wake cycle is and their sleep duration</p>

<p>&lt;&lt;insert slide 4; Timecode (00:02:27). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Study Design (cont)<sup> [5]</sup></strong></p>

<p>&#8226;	Mean sleep-onset latency over the 5 naps was assessed</p>

<p>&#8226;	 MSLT measures the time to fall asleep</p>

<p>&lt;&lt;insert slide 5; Chapter Title: Methods; Timecode (00:03:30). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Demographic Characteristics<sup>[5]</sup>  </strong></p>

<p>&#8226;	Study population included mostly men with a mean ESS score of 16.3</p>

<p>&#8226;	Even among patients with OSA, that is a lot of subjective sleepiness</p>

<p>&lt;&lt;insert slide 6; Chapter Title: Results; Timecode (00:04:20). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Results<sup>[5]</sup></strong></p>

<p>&#8226;	Despite adequate treatment and low Apnea&#160;Hypopnea Index (AHI), 31% were pathologically hypersomnolent</p>

<p>&lt;&lt;insert slide 7; Chapter Title: Conclusion; Timecode (00:04:47). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Conclusion</strong></p>

<p>&#8226;	Findings:<strong> </strong></p>

<p><tt>o	</tt>Not a strong correlation between subjective ratings of sleepiness and that of the objective measure (the MSLT)</p>

<p><tt>o	</tt>Recommendations:</p>

<p>&#9642;	Important to measure both the subjective and objective measures</p>

<p>&#9642;	Very important to obtain actigraphic evaluation to see how well patients are sleeping</p>

<p>&lt;&lt;Component 3  &gt;&gt;</p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>The Treatment of Narcolepsy in Adults: Emerging Therapies</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Solriamfetol:; Timecode (00:00:30). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Solriamfetol<sup>[6,7]</sup></strong></p>

<p>&#8226;	Solriamfetol affects both norepinephrine and dopamine</p>

<p>&#8226;	Most medications used for narcolepsy affect only dopamine</p>

<p>&#8226;	Both neurotransmitters are very important in the control of sleep and wakefulness</p>

<p><tt>o	</tt>Increasing dopamine has an effect on improving alertness </p>

<p><tt>o	</tt>Norepinephrine may have an effect on inhibiting sleep drive </p>

<p>&lt;&lt;insert slide 3; Timecode (00:01:44). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Solriamfetol: Treatment of ES in Narcoleptic Patients With and Without Cataplexy<sup>[7]</sup></strong></p>

<p>&#8226;	12-week, placebo-controlled study </p>

<p>&#8226;	Assessed main measures for sleepiness</p>

<p><tt>o	</tt>Maintenance of Wakefulness Test (MWT) -- an objective measure </p>

<p><tt>o	</tt>ESS -- a subjective measure </p>

<p>&lt;&lt;insert slide 4; Chapter Title:<strong> </strong>Study Results; Timecode (00:02:07). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Solriamfetol: MWT Results<sup>[7,8]</sup></strong></p>

<p>&#8226;	MWT measures the ability to stay awake under soporific conditions using a daytime polysomnographic procedure</p>

<p>&#8226;	Throughout the 12-week study, improvements with both the 300- and 150-mg doses were seen at all timepoints</p>

<p>&lt;&lt;insert slide 5; Chapter Title:<strong> </strong>Study Conclusions; Timecode (00:03:54). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Conclusions<sup>[7]</sup></strong></p>

<p>&lt;&lt;insert slide 6; Timecode (00:04:17). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Conclusions: Adverse Events<sup>[7]</sup></strong></p>

<p>&#8226;	No significant major adverse events (AEs) seen throughout the study</p>

<p>&lt;&lt;insert slide 7; Chapter Title: Use in Practice; Timecode (00:04:47). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Possible Use in Clinical Practice</strong></p>

<p>&lt;&lt;insert slide 8; Chapter Title; Pitolisant Timecode (00:05:25). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Pitolisant<sup>[9]</sup></strong></p>

<p>&#8226;	Pitolisant increases histamine levels in the brain</p>

<p><tt>o	</tt>Histamine is an important neurotransmitter that plays a role in alertness</p>

<p>&#8226;	It is a once-a-day medication taken in the morning</p>

<p>&#8226;	It has become available in the United States under an early access program; it is not yet approved by the US Food and Drug Administration for any use</p>

<p>&lt;&lt;insert slide 9; Chapter Title; Pitolisant Studies Timecode (00:06:45). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Anticataplectic Efficacy of Pitolisant<sup>[9]</sup></strong></p>

<p>&lt;&lt;insert slide 10; Timecode (00:07:06). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Double-Blind, 7-Week Study of Pitolisant vs Placebo: Results<sup>[9]</sup></strong></p>

<p>&lt;&lt;insert slide 11; Timecode (00:07:15). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Open-Label, 12-Month Study of Pitolisant: Results<sup>[9]</sup></strong></p>

<p>&#8226;	Improvement in weekly rate of cataplexy (WRC) was observed at month 1 and was maintained through month 12</p>

<p>&lt;&lt;insert slide 12; Timecode (00:07:38) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Long-Term Evaluation of Pitolisant Safety and Efficacy in Narcolepsy<sup>[9]</sup></strong></p>

<p>&#8226;	This medication has a good safety profile</p>

<p>&#8226;	No major AEs were seen with pitolisant in this study</p>

<p>&lt;&lt;Component  4 &gt;&gt;</p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Upper Airway Stimulation; Timecode (00:00:43). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Upper Airway Stimulation Therapy<sup>[10]</sup></strong></p>

<p>&#8226;	This therapy is directed at the anatomic factors causing OSA using technology and a device</p>

<p>&#8226;	It uses nerve stimulation to open the airway during sleep</p>

<p>&lt;&lt;insert slide 3; Timecode (00:01:10). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Upper Airway Stimulation </strong></p>

<p>&#8226;	Implanted device is comprised of a stimulator implanted on the hypoglossal nerve and a sensor implanted in the chest</p>

<p>&#8226;	The sensor detects breathing and sends an electrical current to the nerve when the airway needs to open during sleep</p>

<p>&#8226;	This is the first therapy to directly act on the nerve </p>

<p>&lt;&lt;insert slide 4; Chapter Title: Indications; Timecode (00:02:15). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Indications for Use<sup>[11]</sup></strong></p>

<p>&lt;&lt;insert slide 5; Chapter Title: ADHERE Registry Subanaylsis; Timecode (00:03:15). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; ADHERE Registry Analysis<sup>[12,13]</sup></strong></p>

<p>&#8226;	The ADHERE Registry is not FDA mandated </p>

<p>&#8226;	Measures real-world outcomes of upper airway stimulation (UAS)</p>

<p>&lt;&lt;insert slide 6; Timecode (00:04:00) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; ADHERE Registry Analysis: Results<sup>[12]</sup></strong></p>

<p>&lt;&lt;insert slide 7; Timecode  (00:04:53) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Upper Airway Stimulation for OSA: 5-Year Outcomes<sup>[14]</sup></strong></p>

<p>&#8226;	The 5-year follow-up of the original study showed that patients who initially respond well to UAS continued to respond well for 5 years</p>

<p>&lt;&lt;insert slide 8; Chapter Title: BMI and UAS; Timecode (00:05:13) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Association of BMI and UAS Success<sup>[12]</sup></strong></p>

<p>&lt;&lt;Component 5 &gt;&gt;</p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>The Impact of Upper Airway Stimulation on Sleepiness and Blood Pressure in Obstructive Sleep Apnea</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Comparative Study of ESS and BP; Timecode (00:00:24). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Comparing UAS and PAP Effects on ESS and BP<sup>[15]</sup></strong></p>

<p> &lt;&lt;insert slide 3; Chapter Title: Comparative Study Results; Timecode (00:00:50). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Results<sup>[15]</sup></strong></p>

<p>&#8226;	Results showed a slightly better effect on ESS scores with upper airway stimulation (UAS) than continuous positive airway pressure (CPAP) </p>

<p>&#8226;	There was no change in blood pressure</p>

<p>&lt;&lt;insert slide 4; Chapter Title: Comparative Study Conclusions; Timecode (00:01:10)  . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Conclusions<sup>[15]</sup></strong></p>

<p>&lt;&lt;insert slide 5; Chapter Title: Effects of Hypoglossal Nerve Stimulation; Timecode (00:02:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Effects of HNS on Sleep Architecture and MWT in OSA<sup>[16]</sup></strong></p>

<p>&#8226;	Hypoglossal nerve stimulation (HNS) is a novel therapy for patients with OSA that has been shown to reduce AHI</p>

<p>&#8226;	This study evaluated the impact of HNS on sleep architecture and objective level of alertness</p>

<p>&lt;&lt;insert slide 6; Timecode (00:03:00) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Effects of HNS on Sleep Architecture and MWT in OSA: Conclusions<sup>[16]</sup></strong></p>

<p>&#8226;	UAS is tunable during and after implantation</p>

<p>&lt;&lt;Component 6&gt;&gt;</p>

<p><strong>&lt;&lt;Level 1&gt;&gt; The Diagnosis of Pediatric Narcolepsy: The Role of Biomarkers</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction </strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Diagnostic Delays; Timecode (00:00:50). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Diagnostic Challenges in Childhood Narcolepsy<sup>[17]</sup></strong></p>

<p>&#8226;	Diagnostic delays are very common in children and adolescents with narcolepsy </p>

<p>&#8226;	It can take many years for the disease to be recognized and diagnosed</p>

<p>&#8226;	This study looked for additional biomarkers in the polysomnogram that could help improve diagnostic accuracy and determine the epidemiology of pediatric narcolepsy</p>

<p>&lt;&lt;insert slide 3; Chapter Title: Biomarkers  ; Timecode (00:02:35). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;REM Sleep<sup>[18,19]</sup></strong></p>

<p>&#8226;	In normal rapid eye movement (REM) sleep, there is almost no muscle tone, ie, REM atonia </p>

<p>&#8226;	Children and adults with narcolepsy have increased muscle tone during REM sleep, ie, REM without atonia (nRWA)</p>

<p>&#8226;	This study looked at whether nRWA could serve as a biomarker of narcolepsy</p>

<p>&lt;&lt;insert slide 4; Timecode (00:03:16). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Diagnostic Biomarker: nRWA<sup>[18]</sup></strong></p>

<p>&#8226;	This study used the American Academy of Sleep Medicine (AASM) criteria to score nRWA </p>

<p>&lt;&lt;insert slide 5; Timecode (00:04:25). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Diagnostic Biomarker: nRWA Results<sup>[18]</sup></strong></p>

<p>&#8226;	Data from patients with narcolepsy type 1 and type 2 were combined to determine whether nRWA was a significant biomarker that separated them from other groups of patients</p>

<p>&lt;&lt;insert slide 6; Chapter Title: Pediatric Disruptive Nighttime Sleep; Timecode (00:05:38). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;DNS in Children and Adolescents With Narcolepsy<sup>[20]</sup></strong></p>

<p>&#8226;	Because it is not known how to objectively define disrupted nighttime sleep (DNS) in pediatric narcolepsy, this study sought to examine this parameter</p>

<p>&#8226;	Studies were rescored using AASM criteria to eliminate confounding of different scoring criteria and scorers</p>

<p>&lt;&lt;insert slide 7; Timecode (00:06:39). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; DNS in Children and Adolescents With Narcolepsy Findings<sup>[20]</sup></strong></p>

<p>&lt;&lt;Component 7  &gt;&gt;</p>

<p><strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Advances in Treating Pediatric Narcolepsy</strong></p>

<p>&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Sodium Oxybate Study; Timecode (00:00:25). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Sodium Oxybate in Children and Adolescents with Narcolepsy: Study Design<sup>[21]</sup></strong></p>

<p><strong>&#8226;	</strong>Several presentations and posters focused on providing additional data from the pediatric sodium oxybate trial that was conducted last year</p>

<p>&lt;&lt;insert slide 3; Chapter Title: Study Results; Timecode (00:00:57). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt;Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period<sup>[21]</sup></strong></p>

<p><strong>&#8226;	 </strong>Ruoff and colleagues examined the results of the Clinical Global Impression scales </p>

<p>&lt;&lt;insert slide 4; Timecode (00:01:40). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period (cont)<sup>[21]</sup></strong></p>

<p>&lt;&lt;insert slide 5;Chapter Title: Adverse Events; Timecode (00:02:40). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;</strong> <strong>Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period (cont)<sup>[21]</sup></strong></p>

<p><strong>&#8226;	</strong>More than 10% of patients reported the following AEs: nocturnal enuresis, nausea, vomiting, headache, and weight loss</p>

<p>&lt;&lt;insert slide 6; Chapter Title: Effects on Development; Timecode (00:02:56) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;Effects of Sodium Oxybate on Weight, Height, and Pubertal Development<sup>[22,23,24]</sup></strong></p>

<p><strong>&#8226;	</strong>Obesity and being overweight is a clinical problem in pediatric narcolepsy </p>

<p><strong>&#8226;	</strong>In this study, the investigators looked at how weight, height, and puberty changed with sodium oxybate use over 1 year </p>

<p>&lt;&lt;insert slide 7;<strong> </strong>Timecode(00:03:38) . &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;Effects of Sodium Oxybate on Weight, Height, and Pubertal Development: Study Findings<sup>[22]</sup></strong></p>

<p><strong>&#8226;	</strong>When the study began, 64.2% of study participants were categorized as being obese or overweight</p>

<p><strong>&#8226;	</strong>Gradual weight loss occurred in participants over 1 year</p>

<p><strong>&#8226;	</strong>By the end of this study, more subjects were in the normal-weight category, and fewer were obese or overweight (9% fewer)</p>

<p>&lt;&lt;insert slide 8; Chapter Title: Long-term Effects; Timecode (00:04:20). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;</strong> <strong>Long-Term Effects of Sodium Oxybate in Pediatric Patients<sup>[25]</sup></strong></p>

<p><strong>&#8226;	</strong>Cataplexy control and daytime sleepiness remained fairly stable during the 1-year period </p>

<p><strong>&#8226;	</strong>Depression, anxiety scores, and suicidality measures remained within the average range during the study </p>

<p>&lt;&lt;insert slide 9; Chapter Title: Disease Burden Analysis; Timecode (00:05:24). &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;</strong> <strong>Disease Burden in Pediatric Narcolepsy<sup>[26]</sup></strong></p>

<p><strong>&#8226;	</strong>This claims-based analysis of healthcare utilization assessed demand and costs in a group of children and adolescents with narcolepsy </p>

<p><strong> </strong>&lt;&lt;insert slide 10; Chapter Title: Thank you; Timecode (00:06:31). &gt;&gt;  </p>

<p><strong>&lt;&lt;Level 2&gt;</strong> <strong>Thank You</strong></p>

<p><strong><em>Mandatory Insertion after Main CONTENT with abridged Transcripts:</em></strong></p>

<p><em>This content has been condensed for improved clarity.</em></p>